Dermatology · Brooklyn, NY
NPI
1134226665
Since 2006
Specialty
Dermatology
Code 207N00000X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
2511 Ocean Ave, Suite 101
Brooklyn, NY, 11229
Phone (718) 332-6080
Medicare paid, 2024
$158K
10,255 services
Medicare patients, 2024
579
Average age 79
Drug cost, 2024
$914K
2,325 prescriptions
Company payments, 2025
$1,419
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Marina Zabezhanskaya was code J7345 (aminolevulinic acid hcl for topical administration, 10% gel, 10 mg), 8,200 times for 31 patients. In total Marina Zabezhanskaya billed 10,255 services in 62 codes, and Medicare paid $158K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2010-10-12.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J7345 Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg | Office | 8,200 | 31 | $1.33 | $11K |
| 99212 Office E&M - Established | Office | 504 | 318 | $48.90 | $25K |
| 17003 Destruction Skin Lesion | Office | 326 | 76 | $5.83 | $1,901 |
| 11102 Skin Biopsy | Office | 255 | 219 | $90.61 | $23K |
| 99202 Office E&M - New | Office | 221 | 221 | $60.21 | $13K |
| 99213 Office E&M - Established | Office | 175 | 155 | $78.81 | $14K |
| 17000 Destruction Skin Lesion | Office | 153 | 123 | $49.15 | $7,519 |
| 11103 Skin Biopsy | Office | 73 | 53 | $45.77 | $3,341 |
| 96574 Skin | Office | 41 | 31 | $252.79 | $10K |
| 12032 Wound Repair - All Levels | Office | 38 | 34 | $218.66 | $8,309 |
| 99203 Office E&M - New | Office | 37 | 37 | $97.60 | $3,611 |
| 99441 Telephone Services | Office | 24 | 18 | $28.69 | $689 |
| 99442 Telephone Services | Office | 18 | 13 | $59.32 | $1,068 |
| 12052 Wound Repair - All Levels | Office | 15 | 13 | $249.54 | $3,743 |
| 11603 Skin Lesion Excision | Office | 14 | 13 | $136.17 | $1,906 |
By year: 2022 $200K for 7,083 services; 2023 $189K for 8,882 services; 2024 $158K for 10,255 services.
Medicare prescription drug claims, 2024
In 2024, the drug Marina Zabezhanskaya prescribed most often to Medicare patients was Ammonium Lactate, with 358 prescriptions and refills. In total Marina Zabezhanskaya wrote 2,325 Medicare prescriptions that cost $914K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ammonium Lactate Generic | 358 | 376 | 106 | $6,130 |
| Ciclopirox Ciclopirox Olamine | 239 | 249 | 108 | $3,689 |
| Betamethasone Diprop Augmented Betamethasone/Propylene Glyc | 174 | 175 | 66 | $12K |
| Clobetasol Propionate Generic | 147 | 148 | 62 | $6,649 |
| Betamethasone Dipropionate Generic | 135 | 136 | 89 | $6,291 |
| Azelaic Acid Generic | 119 | 119 | 43 | $14K |
| Finacea Azelaic Acid | 116 | 121 | 44 | $49K |
| Mometasone Furoate Generic | 99 | 99 | 61 | $1,794 |
| Nystatin Generic | 97 | 97 | 29 | $1,876 |
| Nyamyc Nystatin | 76 | 76 | 27 | $1,517 |
| Silver Sulfadiazine Generic | 63 | 63 | 33 | $409 |
| Metronidazole Generic | 62 | 62 | 14 | $3,442 |
| Mupirocin Generic | 60 | 60 | 31 | $286 |
| Calcipotriene Generic | 44 | 44 | Under 11 | $7,125 |
| Valacyclovir Valacyclovir Hcl | 44 | 44 | 21 | $327 |
Brand drugs: - claims; generic drugs: 1,967 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Marina Zabezhanskaya $1,419 ($1,419 in general payments such as food, travel and fees) from 16 companies. The largest payer was Abbvie Inc. with $270.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 10 | $270 |
| Pfizer Inc. PFE | 11 | $255 |
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 11 | $217 |
| Amgen Inc. AMGN | 5 | $112 |
| MIMEDX Group, Inc. MDXG | 2 | $91.88 |
| Incyte Corporation INCY | 4 | $89.98 |
| Organon LLC OGN | 3 | $68.28 |
| Janssen Biotech, Inc. JNJ | 3 | $65.23 |
| Biofrontera Inc. | 3 | $59.98 |
| STRATA Skin Sciences, Inc. SSKN | 3 | $59.97 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.